Actor Vikram spoke about Malayalam star Mohanlal while promoting his upcoming film Veera Dheera Sooran. Here's what he said. Actors Vikram and Mohanlal’s upcoming films Veera Dheera Sooran and ...

Vikram's much-anticipated film 'Veera Dheera Sooran' hits theatres with an opening of Rs 3.25 crore across India. The film experienced slow initial reactions but showed growth in evening and night ...

Vikram's film 'Veera Dheera Sooran: Part 2' faces legal troubles, delaying its release to after 11 AM on March 27, 2025. Morning shows in India and premiere shows in the US are canceled.

Tamil actor Chiyaan Vikram recently attended a screening of his highly anticipated film Veera Dheera Sooran Part 2 at Chennai's iconic Sathyam Theatre. In a surprising yet down-to-earth gesture ...

Hindu Nav Varsha, beginning on March 30, 2025, marks the start of Vikram Samvat 2082. Celebrations vary across regions, including Gudi Padwa in Maharashtra, Yugadi in Andhra Pradesh, Poila Baisakh ...

Chiyaan Vikram-starrer Veera Dheera Sooran: Part 2 is a dramatic dance-off between all these characters, tensed and annoyed (perhaps for being interrupted while dining! Maybe this is a warning ...

Vikram extensively promoted the film before its release, so fans who booked tickets for the morning shows were disappointed. Veera Dheera Sooran's team has yet to address the issue publicly.

Few companies embody the term 'pharma giant' as much as Pfizer. Here we take a look at the colourful history of one of the biggest drugmakers in the world. Pfizer was founded in 1849 by two recent ...

Veera Dheera Sooran, starring Vikram in the lead role, witnessed a slow start at the box office. The film hit the theatres on March 27 and had high expectations. Unfortunately, the film seems to ...

Veera Dheera Sooran Box Office Collection Day 1: Chiyaan Vikram's action movie has taken the Kollywood box office by storm with decent show on first day, March 27. The Tamil movie directed by S U ...

Major stocks in the sector took notable hits, including but not at all limited to Pfizer (NYSE: PFE), Merck (NYSE: MRK), and Eli Lilly (NYSE: LLY). Pfizer (NYSE:PFE) recently saw the European ...

Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in front of investors, aiming to add eight ...